Australasian Science: Australia's authority on science since 1938

Psychedelic Microdosing Doesn’t Meet User Expectations

Taking very small amounts of psychedelic substances on a regular basis – called “microdosing” – may improve psychological and cognitive functioning but the effects don’t match users’ expectations, according to a study published in PLOS ONE (

Microdosing of substances like LSD and psilocybin (found in magic mushrooms) has had a recent surge in popularity, with proponents claiming wide-ranging benefits, including enhanced productivity, concentration, creativity, mood and well-being, all without the “high” of psychedelics.

In the first published longitudinal study to test these claims, Macquarie University researchers recruited 98 “microdosers” from online forums and tracked their experiences over a 6-week period. Participants reported significant decreases in depression, stress and distractibility, and increased feelings of connection to their experiences. Many felt a boost in positive attitude, but this did not generally linger beyond the first day of microdosing.

Because many people who experiment with microdosing hold strong beliefs about its positive benefits, the researchers conducted an additional study comparing both new and experienced microdosers’ expectations to the actual effects experienced by participants in the main study.

Lead author of the study, Dr Vince Polito, said that while some of the anticipated effects of microdosing were supported by the study, many were not, and there were some unexpected negative experiences. “Glowing media reports have presented microdosing as a panacea, able to improve virtually all aspects of life, so it is not surprising that participants have strong expectations,” Polito said.

“While there were clear positive impacts on depression, stress and concentration, we saw no evidence of expected improvements to creativity, well-being and mindfulness. Participants also experienced increased neuroticism, which is a risk not generally discussed by supporters of microdosing.”

Co-author Prof Dick Stevenson added: “The regulatory restrictions around psychoactive substances make it very difficult to systematically study their effects. However, as interest in microdosing grows, including its possibilities for people’s productivity at work, this study is an important first step in exploring users’ varying experiences, and it clearly indicates the need for further, carefully controlled studies of microdosing’s potential benefits and risks.”